Last reviewed · How we verify
RAUWOLFIA SERPENTINA (RAUWOLFIA SERPENTINA ROOT)
RAUWOLFIA SERPENTINA (generic name: RAUWOLFIA SERPENTINA ROOT) is a drug developed by PVT FORM. It is currently FDA-approved.
At a glance
| Generic name | RAUWOLFIA SERPENTINA ROOT |
|---|---|
| Sponsor | PVT FORM |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- NCT00000484 (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAUWOLFIA SERPENTINA CI brief — competitive landscape report
- RAUWOLFIA SERPENTINA updates RSS · CI watch RSS
- PVT FORM portfolio CI
Frequently asked questions about RAUWOLFIA SERPENTINA
What is RAUWOLFIA SERPENTINA?
RAUWOLFIA SERPENTINA (RAUWOLFIA SERPENTINA ROOT) is a pharmaceutical drug developed by PVT FORM.
Who makes RAUWOLFIA SERPENTINA?
RAUWOLFIA SERPENTINA is developed and marketed by PVT FORM (see full PVT FORM pipeline at /company/pvt-form).
What is the generic name of RAUWOLFIA SERPENTINA?
RAUWOLFIA SERPENTINA ROOT is the generic (nonproprietary) name of RAUWOLFIA SERPENTINA.
What development phase is RAUWOLFIA SERPENTINA in?
RAUWOLFIA SERPENTINA is FDA-approved (marketed).
Related
- Manufacturer: PVT FORM — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing